182 related articles for article (PubMed ID: 23412108)
1. Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma.
Naing A; Lorusso P; Fu S; Hong D; Chen HX; Doyle LA; Phan AT; Habra MA; Kurzrock R
Br J Cancer; 2013 Mar; 108(4):826-30. PubMed ID: 23412108
[TBL] [Abstract][Full Text] [Related]
2. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors.
Naing A; LoRusso P; Fu S; Hong DS; Anderson P; Benjamin RS; Ludwig J; Chen HX; Doyle LA; Kurzrock R
Clin Cancer Res; 2012 May; 18(9):2625-31. PubMed ID: 22465830
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer.
Naing A; Kurzrock R; Burger A; Gupta S; Lei X; Busaidy N; Hong D; Chen HX; Doyle LA; Heilbrun LK; Rohren E; Ng C; Chandhasin C; LoRusso P
Clin Cancer Res; 2011 Sep; 17(18):6052-60. PubMed ID: 21750201
[TBL] [Abstract][Full Text] [Related]
4. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial.
Schwartz GK; Tap WD; Qin LX; Livingston MB; Undevia SD; Chmielowski B; Agulnik M; Schuetze SM; Reed DR; Okuno SH; Ludwig JA; Keedy V; Rietschel P; Kraft AS; Adkins D; Van Tine BA; Brockstein B; Yim V; Bitas C; Abdullah A; Antonescu CR; Condy M; Dickson MA; Vasudeva SD; Ho AL; Doyle LA; Chen HX; Maki RG
Lancet Oncol; 2013 Apr; 14(4):371-82. PubMed ID: 23477833
[TBL] [Abstract][Full Text] [Related]
5. A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer.
Ma CX; Suman VJ; Goetz M; Haluska P; Moynihan T; Nanda R; Olopade O; Pluard T; Guo Z; Chen HX; Erlichman C; Ellis MJ; Fleming GF
Breast Cancer Res Treat; 2013 May; 139(1):145-53. PubMed ID: 23605083
[TBL] [Abstract][Full Text] [Related]
6. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab.
Busaidy NL; LoRusso P; Lawhorn K; Hess KR; Habra MA; Fu S; Hong DS; Chen HX; Doyle LA; Kurzrock R; Naing A
Oncologist; 2015 Jul; 20(7):737-41. PubMed ID: 26054632
[TBL] [Abstract][Full Text] [Related]
7. A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer.
McHugh DJ; Chudow J; DeNunzio M; Slovin SF; Danila DC; Morris MJ; Scher HI; Rathkopf DE
Clin Genitourin Cancer; 2020 Jun; 18(3):171-178.e2. PubMed ID: 32057715
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of cixutumumab in combination with temsirolimus in pediatric patients and young adults with recurrent or refractory sarcoma: a report from the Children's Oncology Group.
Wagner LM; Fouladi M; Ahmed A; Krailo MD; Weigel B; DuBois SG; Doyle LA; Chen H; Blaney SM
Pediatr Blood Cancer; 2015 Mar; 62(3):440-4. PubMed ID: 25446280
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
10. A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours.
Wilky BA; Rudek MA; Ahmed S; Laheru DA; Cosgrove D; Donehower RC; Nelkin B; Ball D; Doyle LA; Chen H; Ye X; Bigley G; Womack C; Azad NS
Br J Cancer; 2015 Jan; 112(1):24-31. PubMed ID: 25268371
[TBL] [Abstract][Full Text] [Related]
11. The combination of insulin-like growth factor receptor 1 (IGF1R) antibody cixutumumab and mitotane as a first-line therapy for patients with recurrent/metastatic adrenocortical carcinoma: a multi-institutional NCI-sponsored trial.
Lerario AM; Worden FP; Ramm CA; Hesseltine EA; Stadler WM; Else T; Shah MH; Agamah E; Rao K; Hammer GD
Horm Cancer; 2014 Aug; 5(4):232-9. PubMed ID: 24849545
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma.
El-Khoueiry AB; O'Donnell R; Semrad TJ; Mack P; Blanchard S; Bahary N; Jiang Y; Yen Y; Wright J; Chen H; Lenz HJ; Gandara DR
Cancer Chemother Pharmacol; 2018 May; 81(5):957-963. PubMed ID: 29520435
[TBL] [Abstract][Full Text] [Related]
13. A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report.
Fouladi M; Perentesis JP; Wagner LM; Vinks AA; Reid JM; Ahern C; Thomas G; Mercer CA; Krueger DA; Houghton PJ; Doyle LA; Chen H; Weigel B; Blaney SM
Clin Cancer Res; 2015 Apr; 21(7):1558-65. PubMed ID: 25467181
[TBL] [Abstract][Full Text] [Related]
14. Advanced gynecologic malignancies treated with a combination of the VEGF inhibitor bevacizumab and the mTOR inhibitor temsirolimus.
Piha-Paul SA; Wheler JJ; Fu S; Levenback C; Lu K; Falchook GS; Naing A; Hong DS; Tsimberidou AM; Kurzrock R
Oncotarget; 2014 Apr; 5(7):1846-55. PubMed ID: 24742900
[TBL] [Abstract][Full Text] [Related]
15. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of bevacizumab and temsirolimus combination therapy for recurrent glioblastoma multiforme.
Lassen U; Sorensen M; Gaziel TB; Hasselbalch B; Poulsen HS
Anticancer Res; 2013 Apr; 33(4):1657-60. PubMed ID: 23564811
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
18. Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer.
Ganesan P; Piha-Paul S; Naing A; Falchook G; Wheler J; Janku F; Zinner R; Laday S; Kies M; Tsimberidou AM
Invest New Drugs; 2013 Dec; 31(6):1505-13. PubMed ID: 23982248
[TBL] [Abstract][Full Text] [Related]
19. A dual-specific anti-IGF-1/IGF-2 human monoclonal antibody alone and in combination with temsirolimus for therapy of neuroblastoma.
Zhao Q; Tran H; Dimitrov DS; Cheung NK
Int J Cancer; 2015 Nov; 137(9):2243-52. PubMed ID: 25924852
[TBL] [Abstract][Full Text] [Related]
20. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
